sj-docx-1-cpx-10.1177_21677026231213368 – Supplemental material for Reinforcement-Learning-Informed Queries Guide Behavioral Change

Supplemental material, sj-docx-1-cpx-10.1177_21677026231213368 for Reinforcement-Learning-Informed Queries Guide Behavioral Change by Vanessa M. Brown, Jacob Lee, John Wang, Brooks Casas and Pearl H. Chiu in Clinical Psychological Science</p

The utility weights by age and risk groups and pneumococcal disease.

<p>The utility weights by age and risk groups and pneumococcal disease.</p

Results of one-way sensitivity analysis: PCV13 versus PPSV23.

<p><b>The base value of PPSV23 effectiveness against NPP was assumed as 0%, and sensitivity analysis was conducted by varying the value from 20% to 50%, as presented in the 2x2 table.</b> (PPSV23, 23-valent pneumococcal polysaccharide vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; IPD, invasive pneumococcal disease; NPP, non-bacteremic pneumococcal pneumonia).</p

Univariate and multivariate analyses for clinical variables of laboratory-confirmed influenza.

<p>CI, Confidence interval.</p>†<p>Indicates the variable was not entered in logistic regression analysis as it was not significant in univariate analysis.</p

Demographic characteristics of the study participants.

<p>^a Seventeen (1.5%) participants were positive for both influenza A and B in the rapid antigen test. The cases were suspected to be influenza A and B co-infections according to the manufacturer’s instructions.</p><p>^b Some patients had one or more comorbidities.</p><p>Demographic characteristics of the study participants.</p

Accuracy of diverse influenza-like illness symptom combinations, stratified by age and influenza activity.

<p>Positive LR, Positive likelihood ratio; Negative LR, Negative likelihood ratio.</p><p>Note: Young age group (aged 18–29 years) (<i>n</i> = 307); middle age group (aged 30–65 years) (<i>n</i> = 789); old age group (aged 65+ years) (<i>n</i> = 321).</p

Input data for the cost-effectiveness model of pneumococcal disease burden.

<p>Input data for the cost-effectiveness model of pneumococcal disease burden.</p

Subgroup analysis of clinical variables for laboratory-confirmed influenza, stratified by age and influenza activity: multivariate analysis (odds ratios (95% CI)).

†<p>Indicates that the variable was not entered in logistic regression analysis as it was not significant in univariate analysis.</p>*<p>Indicates that the <i>p</i>-value of the data <0.05 in logistic regression analysis.</p><p>Note: Epidemic period (25 December 2011 [week 53]–5 May 2012 [week 18]) (<i>n</i> = 1811), non-epidemic period (25 September 2011 [week 40]–24 December 2011 [week 52], 6 May 2012 [week 19]–2 July 2012 [week 22]) (<i>n</i> = 147).</p

Analyses of cost-effectiveness according to vaccination strategy.

<p>Analyses of cost-effectiveness according to vaccination strategy.</p

Estimates of PPSV23 and PCV13 vaccine effectiveness (VE) against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia.

<p>Estimates of PPSV23 and PCV13 vaccine effectiveness (VE) against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia.</p